The Effect of Variable Dose and Release Kinetics on Neointimal Hyperplasia Using a Novel Paclitaxel-Eluting Stent Platform
The Paclitaxel In-Stent Controlled Elution Study (PISCES)
Patrick W. Serruys, MD, PhD, FACC*,*,
Georgios Sianos, MD, PhD*,
Alexandre Abizaid, MD ,
Jiro Aoki, MD*,
Peter den Heijer, MD, PhD ,
Hans Bonnier, MD, PhD ,
Pieter Smits, MD, PhD||,
Dougal McClean, MD¶,
Stefan Verheye, MD, PhD#,
Jorge Belardi, MD**,
Jose Condado, MD,
Michel Pieper, MD,
Louise Gambone, BA,
Marco Bressers, MSc||||,
Janette Symons||||,
Eduardo Sousa, MD and
Frank Litvack, MD, FACC
*Erasmus Medical Center, Rotterdam, the Netherlands
Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
Amphia Ziekenhuis, Bredathe Netherlands
Catharina Ziekenhuis, Eindhoventhe Netherlands
|| Medisch Centrum Rijnmond-Zuid, Rotterdam, the Netherlands
¶ Christchurch Hospital, Christchurch, New Zealand
# Academisch Ziekenhuis Middelheim, Antwerp, Belgium
** Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
Hospital Miguel Perez Carreno, Caracas, Venezuela
Herzzentrum Bodensee, Kreuzlingen, Switzerland
Conor Medsystems, Menlo Park, California
|| || Cardialysis, Rotterdam, the Netherlands
View larger version (103K):
[in a new window]
|
Figure 1 Single cell of the Conor stent showing the intra-strut wells (a) filled with erodable polymer (b). The ductile hinge allows full deployment of the stent without deformation of the wells containing the drug. The release of the drug (c) can be either uni-directional toward the vessel wall (abluminal) or bidirectional toward the lumen of the vessel (luminal) and the vessel wall.
|
|
View larger version (24K):
[in a new window]
|
Figure 2 The six kinetic elution profiles, with their respective duration of elution (days, x axis), kinetic release (zero or first order; see slope of curve), cumulative dose (µg, y axis), and direction of elution (*bidirectional release, **abluminal (mural) release only). PTX = paclitaxel.
|
|
|
